A Weak Neutralizing Antibody Response to Hepatitis C Virus Envelope Glycoprotein Enhances Virus Infection by Meyer, Keith et al.
A Weak Neutralizing Antibody Response to Hepatitis C
Virus Envelope Glycoprotein Enhances Virus Infection
Keith Meyer
1, Arup Banerjee
1, Sharon E. Frey
1, Robert B. Belshe
1,2, Ranjit Ray
1,2*
1Department of Internal Medicine, Saint Louis University, St. Louis, Missouri, United States of America, 2Molecular Microbiology & Immunology, Saint Louis University, St.
Louis, Missouri, United States of America
Abstract
We have completed a phase 1 safety and immunogenicity trial with hepatitis C virus (HCV) envelope glycoproteins, E1 and
E2, with MF59 adjuvant as a candidate vaccine. Neutralizing activity to HCV genotype 1a was detected in approximately
25% of the vaccinee sera. In this study, we evaluated vaccinee sera from poor responders as a potential source of antibody
dependent enhancement (ADE) of HCV infection. Sera with poor neutralizing activity enhanced cell culture grown HCV
genotype 1a or 2a, and surrogate VSV/HCV pseudotype infection titer, in a dilution dependent manner. Surrogate
pseudotypes generated from individual HCV glycoproteins suggested that antibody to the E2 glycoprotein; but not the E1
glycoprotein, was the principle target for enhancing infection. Antibody specific to FcRII expressed on the hepatic cell
surface or to the Fc portion of Ig blocked enhancement of HCV infection by vaccinee sera. Together, the results from in vitro
studies suggested that enhancement of viral infectivity may occur in the absence of a strong antibody response to HCV
envelope glycoproteins.
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Introduction
HCV continues to be a major global public health problem
despite significant advances in interferon based treatment. New
generation of specific antivirals are entering clinical trials; and the
use of combination therapy is likely to diminish the development
of resistant variants, and provide effective virus control and
eradication. The use of cell culture grown HCV and VSV/HCV
pseudotype as a surrogate model have proven to be important
tools in understanding the role of virus envelope glycoproteins for
interactions with cell surface proteins [1,2,3,4,5]. The entry stage
of viral replication constitutes a target for neutralizing antibodies
as well as pharmacologic agents. Several lines of evidence suggest
important contributions for the two HCV envelope glycoproteins
(E1 and E2) in HCV entry using pseudotype models and include:
(i) Initial contact of HCV partly depends on sulfated polysaccha-
rides present on mammalian cells and this contact appears to be
stronger with the E2 glycoprotein [2,3,5,6,7,8,9]. (ii) CD81 may
play a role in virus infectivity through interaction with E2
[2,3,10,11]. (iii) Virus titer decreases with interruption of LDL-R
activity and this may be mediated via an E1 specific interaction
[2,3]. These observations suggest that the two different forms of
recombinant HCV envelope glycoproteins (chimeric E1-G/E2-G
used in VSV pseudotype generation or unmodified E1–E2 used in
HIV or MuLV derived pseudotype) display similar functional
profiles, and that more than one cellular protein may be
responsible for binding and entry of virus particles into
hepatocytes. Claudin-1 (CLDN1) has been shown to act at a
post-binding stage of HCV [12], although the precise function of
CLDN1 in the orchestration of HCV entry is under investigation.
Specific entry factors of HCV, like CD81 or SR-B1, may associate
with CLDN1 on the basolateral surface of polarized hepatocytes
and facilitate HCV cell to cell spread [13,14]. A recent report
suggests that tyrosine kinases mediate HCV entry by regulating
CD81-claudin-1 co-receptor associations and HCV glycoprotein
dependent membrane fusion [15]. Thus, multiple cellular proteins
and cell surface receptors may be involved in an interaction
between HCV and host cells for virus entry.
HCV patient derived glycoproteins exhibit marked differences
in susceptibility to serum neutralizing antibodies [16]. HCV may
exist in the blood as free virus or complexed with antibodies. A
large percentage of sera from chronically HCV infected patients or
vaccinee sera bind to HCV envelope glycoproteins, but fail to
efficiently neutralize infection, and some of these serum antibodies
as well as human monoclonal antibodies enhance pseudotype
infectious titer [17,18,19,20,21]. This enhancement may be due to
the presence of non-neutralizing antibodies and/or antibodies of
low affinity.
Antibody-dependent enhancement of infection has been
observed in vivo in animal models and among individuals
vaccinated against certain viruses, such as flavivirus (yellow fever,
dengue), HIV-1, Ebola virus, and Hantavirus [22,23]. Increased
infection occur both through interactions with Fc receptors, and
receptors for complement in different human cell lines
[24,25,26,27,28]. The ability of sera to enhance HIV-1 infection
in the presence of complement is associated with a progression
towards AIDS [23,24,25,29], and an in vivo correlate of increased
viral burden and antigenemia in a SIV/macaque model [30].
Viruses elicit antibodies that enhance infectivity through the
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the Fc portion of the antibodies; leading to an increase in viral
uptake, with an accompanying increase in replication and higher
viral titer [31,32]. Understanding the nature of antigen-antibody
interactions, along with the role of the complement system in
HCV infection may help to clarify the poor performance of anti-
HCV specific immunoglobulins in disease progression.
In this study, we evaluated the modulation of cell culture grown
HCV and VSV derived pseudotype infectivity by antibodies
obtained from volunteers vaccinated against HCV in the presence
or absence of complement. The results indicate that enhancement
of viral infectivity may occur in the absence of a strong antibody
response to HCV envelope glycoproteins.
Methods
Vaccinee sera
A randomized, double-blinded, placebo-controlled study
(DMID 01–012) was completed after approval by the Saint Louis
University Institutional Review Board. All subjects provided
informed consent, and the work was conducted with Institutional
Approval (IRB # 15719). Immunizations included 4 doses of
purified Chinese hamster ovarian cell–derived full-length recom-
binant E1/E2 glycoproteins of HCV genotype 1a with the MF59
adjuvant (Novartis) in 3 different volunteer groups. The volunteers
in each group were immunized 4 times (at 0, 4, 24, and 48 weeks)
with 4, 20, or 100 mg of E1/E2 per vaccine dose and MF59
adjuvant. Sixteen volunteers in each group received vaccine using
one of the dosage levels and 4 received a placebo control in each
group. Serum samples were collected from the volunteers at
different time points (0, 6, 26, 50, and 64 weeks) for testing, heat
inactivated, and the nature of the antibody responses were
characterized [21,33]. For this study; serum drawn at week 64
(16 weeks after the fourth immunization) was used to evaluate the
potential of non-neutralizing sera to affect HCV titer.
Generation of HCV in cell culture
HCV genotype 1a (clone H77) or HCV genotype 2a (clone
JFH1) were grown in immortalized human hepatocytes (IHH) as
previously described [4]. Virus was harvested from cells and
clarified by low speed centrifugation, followed by filtration through
a 0.45-mm cellulose acetate membrane (Nalgene, Rochester, NY).
Cell culture grown HCV (HCVcc) were aliquoted and stored at
270uC for single use. RNA (IU/ml) was quantified by real-time
polymerase chain reaction (Prism 7500 real-time thermocycler;
ABI) with the use of HCV analyte-specific reagents (ASR, Abbott)
from the Pathology Clinical Laboratory at Saint Louis University.
Virus titer was measured from cell culture supernatant by
fluorescent-focus formation (FFU) assay using HCV specific
reagents. HCV titer was typically calculated between 10
4–10
6
IU/ml and 10
4–10
5 FFU/ml. IU/ml values were normally .10
fold as compared to FFU/ml for HCV genotype 1a, and this
difference was higher with HCV genotype 2a generated in cell
culture.
Assay for HCVcc infectivity
To quantify antibody dependent enhancement (ADE) of HCV
infection by antibody from viral RNA estimation, a predetermined
IU of cell culture grown HCV was exposed to serial dilutions of
vaccinee sera and incubated for 1 h at 37uC prior to addition to
Huh7 cells. Virus containing supernates were incubated with cells
for 3 h at 37
oC. Cells were rinsed twice and incubated at 37uC for
96 h. Cells were rinsed, lysed, and RNA was isolated using the
RNAeasy Miniprep kit (Qiagen). cDNA was generated using a
Superscript III kit (Invitrogen), followed by real-time PCR to
quantify viral RNA titer [34]. A curve of virus dilutions was used
as a comparative control, and 18S RNA was used as an internal
control. The reciprocal serum dilution is given as X, where X is 1/
X.
Further, HCV (clone JFH1) was used to infect Huh7.5 cells
using a predetermined (FFU) number of viral particles as
determined by FFU. Briefly, virus supernates were diluted as a
pool to cover the entire experiment, separated, and treated
individually with vaccinee sera for one hour prior to infection of
Huh7.5 cells. Infected cells were incubated for 72 hours at 37
oC.
Cells were washed three times with phosphate-buffered saline
(PBS) and stained with antibody specific to HCV core (C750,
Thermo Fischer, IL) at a dilution of 1/400 or NS5A (kindly
provided by Chen Liu, University of Florida) at a dilution of 1/
100. Cells were washed three times with PBS, stained with anti-
mouse immunoglobulin (Ig) conjugated with Alexa 568 (Molecular
Probes, Eugene, OR), and mounted for fluorescence microscopy.
Figure 1. Screening for cell culture grown HCV genotype 1a
(clone H77) infectivity in the presence of vaccine sera. The bar
diagrams represent the overall outcome of the vaccinee sera to
interfere with virus infectivity. Enhancing sera are defined as those
which display a .2 fold increase in FFU, while not displaying
neutralization at dilutions between 1:10 and 1:160. Neutralizing sera
are those which display $50% decrease in FFU at a dilution of $1:20
(panel A). Enhancement of cell culture grown HCV genotype 1a
infectivity using serial dilutions of selected vaccinee sera are shown
(panel B). Fold increase in real-time PCR values of HCV RNA with three
representative sera at different dilutions, and a decrease in HCV RNA in
response to a different vaccinee serum are shown.
doi:10.1371/journal.pone.0023699.g001
Antibody Dependent Enhancement of HCV Infection
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gates were titrated for use of optimum dilutions where there was
no background fluorescence. DAPI was used to enhance focus by
nuclear staining prior to imaging. Fluorescence positive infected
cells were observed by microscopy, and counted. A human
monoclonal antibody to HCV E2 glycoprotein (CBH5) was used
as a neutralizing positive control, and HCV negative sera was used
as a further control.
Blocking FcR interactions
A Fab fragment recognizing the Fc region of immunoglobulin
(Sigma, St. Louis, MO) was examined for blocking HCV
infectivity. The Fc-specific Fab fragment was added at the time
of pseudotype/antibody incubation at a concentration of 1ug/ml.
Control virus for this experiment included a duplicate treated with
the Fc specific Fab fragment, with no change in virus titer. The
remainder of the experiment was carried out as described above.
Cell culture grown HCV was diluted to a predetermined FFU for
estimation of IU, and exposed to vaccinee sera in the presence or
absence of an Fc specific Fab fragment and incubated for 1 h at
37
oC. Virus containing supernates were added to cells for 3 h at
37
oC. Cells were rinsed and incubated at 37uC for 96 h. RNA
from infected cells was isolated using a RNAeasy Miniprep kit
(Qiagen). cDNA was prepared using a Superscript III kit, followed
by real-time PCR to quantify enhancement of virus titer. A curve
for virus dilutions was used as a comparative control, and 18S
RNA was used as an internal control.
Figure 2. Enhancement of HCVgenotype 2a (clone JFH1) infectivity by serial dilutions of the selected vaccinee sera. A predetermined
HCV titer was incubated with vaccinee sera for 1 h prior to addition to an Huh-7.5 cell monolayer for infectivity. Fold increase of HCV RNA by real-time
PCR is shown (panels A). Sera were also analyzed for ADE by immunofluorescence, and photomicrographs were captured at 200X magnification
(panel B). A predetermined number of FFU were used to infect Huh-7.5 cells in the presence or absence of vaccinee sera at a 1:80 dilution, followed
by 72 h incubation. HCV protein expression was detected using an antibody specific to the HCV core protein, followed by anti-mouse
immunoglobulin (Ig) conjugated with Alexa 568 (Molecular Probes, Eugene, OR). Cells infected with virus prior treated with vaccinee sera displayed a
greater degree of infection as compared to infected controls in the absence of sera.
doi:10.1371/journal.pone.0023699.g002
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5) were
treated with antibodies directed to respective cellular FcRs (Ancell,
Bay Port, MN) at a concentration of 2ug/ml. Cells were incubated
for 15 minutes in the presence of 1 ug of each individual FcR-
inhibiting antibody prior to adsorption of the virus-antibody
mixture. Viral RNA was quantified by real-time PCR (as above)
and compared to those of control ADE infections in the absence of
an antibody directed specifically against FcR.
Flowcytometry
Cell surface expression of Fc receptors was quantified by flow
cytometry. IHH or Huh7 cells were grown on plastic surface and
detached by treatment with Accutase (Sigma), washed with
phosphate-buffered saline (PBS), and incubated with antibodies
to Fc receptors (CD16, CD32, and CD64 - procured from Ancell,
Bayport, MN) at a concentration of 4 ug/ml, followed by the
addition of a FITC conjugated secondary antibody for staining.
Cells were rinsed and resuspended in methanol free 1%
paraformaldehyde in PBS and gated according to their size
(forward light scatter) and granularity (side light scatter) using a
Becton Dickinson flow cytometer. Surface marker expression on
gated cells was analyzed using FlowJo (Tree Star) and CellQuest
(BD Immunocytometry Systems) software. The Statistica program
was used for analyses of variations.
Pseudotype virus
VSV derived pseudotypes were generated from BHK cells
expressing HCV envelope glycoproteins (E1 and/or E2), with control
virus being derived from cells expressing VSV-G protein as previously
described [3]. Treatmentof VSV/HCV pseudotype with an antiserum
to VSV G did not alter virus titer, suggesting the absence of revertant
VSV G in pseudotype preparation(s), while positive-control virus
incorporating native VSV G exhibited pseudotype neutralization as
previously reported. NMSO3 (1.25 mg/ml) was used for an additional
safeguard from contaminating VSV G glycoprotein reconstitution on
pseudotype virus [3]. The assay for pseudotype infectivity in the
presence or absence of antibody was performed in Huh7 cells as
described earlier [20]. Parental VSV was exposed to the same
experimental conditions for use as a control against nonspecific ADE.
Results
Enhancement of HCVcc infection by vaccinee sera
Vaccination stimulated low levels of antibodies in subjects [21].
Results obtained from experiments examining the neutralization
of cell culture grown HCV (HCVcc) by immunofluorescence
(FFU) displayed the number of neutralizing, non-reactive, or
enhancing vaccine sera as summarized (Fig. 1, panel A). To
further define the ability of non-neutralizing sera to enhance HCV
infectivity, we infected IHH with HCV genotype 1a (clone H77) in
the presence or absence of heat inactivated HCV specific vaccinee
sera. Subsequently, we used a sensitive real-time PCR assay to
quantitate HCV genotype 1a genomic RNA copies to demonstrate
increased levels of virus after antibody mediated enhancement of
HCV infection. The results from three representative sera
displaying at least 3 fold increase in HCV RNA at different
serum dilutions is shown (Fig. 1, panel B). A separate vaccine sera
observed to neutralize both HCVcc and pseudotype was used at
the same dilutions and was observed to strongly neutralize virus
infectivity at all dilutions tested. Sera from pre-vaccinated subjects
did not display any significant reactivity to cell culture grown
HCV in these experiments.
The use of cell culture grown HCV JFH1 has become widely
accepted virus of choice in understanding diverse aspects of HCV.
In our hands, we have observed that the infectious titer of this
virus is much higher and the readout is therefore more convenient.
Higher growth of the HCV2a clone is likely due to a stronger
polymerase activity of the virus [35]. We also examined how these
vaccinee sera react with cell culture grown HCV genotype 2a
(Fig. 2, panel A). Interestingly, vaccinee sera exhibited a higher
level of viral RNA detected upon dilution to 1:80, which could be
attributed to genotype differences. Together, these results display
an increased HCV titer or quantity of genomic RNA in
hepatocytes in the presence of some of the vaccinee sera,
suggesting ADE of HCV infection. A separate vaccine sera
observed to neutralize both HCVcc and pseudotype virus was used
at the same dilutions and was observed to neutralize virus to
higher dilutions (1:320).
Immunofluorescence to detect the level of FFU(Focus Forming
Units) in infected cells was performed to further verify serum
generating ADE of HCV JFH-1 infection. Huh7.5 cells infected with
virus treated with vaccinee sera prior to cell overlay displayed a
distinctly higher level of infection, as evidenced from FFU in all fields
analyzed. A representative series of images are shown (Fig. 2, panel B).
Enhancement of VSV/HCV pseudotype infection by
vaccinee sera
In earlier studies, we have observed a rise in pseudotype plaque
number when serum dilutions fell well below a neutralizing
Figure 3. Weak neutralizing activity of vaccinee sera correlates
with ADE. Vaccinee sera were selected by their ability to enhance or
neutralize of VSV/HCV pseudotype. Sera were serially diluted and
incubated for 1h at 37uC prior to infection of Huh-7.5 cells. Sera with
neutralizing titers (.1/20) did not exhibit ADE at the dilutions tested.
doi:10.1371/journal.pone.0023699.g003
Antibody Dependent Enhancement of HCV Infection
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inactivated vaccinee sera were tested for their ability to enhance
infection at dilutions which fell below their normal neutralizing
thresholds in a cell line which is permissive for HCV infection. A
pseudotype-vaccinee serum mixture was subjected to plaque titer
determination, and the calculated values (percentage of control) are
shown (Fig. 3). Sera from healthy uninfected donors enhanced
pseudotypeinfectivity by less than 20%, andthispropertydecreased
with increasing serum dilutions (data not shown). Sera from six
HCV-vaccinated patients with a poor neutralizing activity exhibited
enhancement over a range of serum dilutions (Fig. 3, panel A).
Interestingly, representative sera which exhibited the strongest
ability to neutralize pseudotype virus (sera # 119, 120, 121, and
122) failed to exhibit any significant enhancing titer (Fig. 3, panel B).
However, the ability to successfully neutralize pseudotype virus did
not correlate with an inability to also enhance infection at higher
dilutions, as two sera which displayed a modest level of
neutralization (sera # 117 and 118) were observed to also enhance
infection in a similar manner as above. The data from this set of
experiments suggested that an inhibition of virus infection occurs
when the ratio of neutralizing antibody to virus is high; whereas in a
manner similar to that observed in context to dengue hemorrhagic
fever, enhancement occurs when this ratio is reversed [36].
Enhancement of VSV/HCV pseudotype infection by E2
glycoprotein specific antibodies
We have observed a rise in pseudotype plaque number when
serum dilutions fell well below a neutralizing concentration. To
further examine this observation, vaccinee sera were tested for their
reactivity at dilutions which fell below their normal neutralizing
thresholds for E1 and/or E2 pseudotype. The use of each individual
glycoprotein alone on a VSV backbone exhibited ligand binding
unique to the individual glycoprotein; although virus titer was
significantly less than that seen when the HCV envelope
glycoproteins were both incorporated into the pseudotype virus.
However, use of the envelope protein alone on HIV based
pseudotype displayed a low level of fluorescence above background
(potentially due to poor incorporation of these internally expressed
glycoproteins), making the use of this pseudotype difficult. The
pseudotype-vaccinee serum mixture was subjected to plaque titer
determination, and the calculated values (percentage of control) are
shown from sera from 8 subjects (Fig. 4, panels A–H). Six
representative vaccinee sera (sera # 111, 112, 115, 116, 117, 118)
exhibited an enhancing activity of the pseudotype generated from
E2 alone or from E1/E2 covering a broad range of serum dilutions.
However, pseudotype generated with E1 glycoprotein alone
exhibited some degree of neutralization by all 6 vaccinee sera
which displayed ADE with no significant enhancement. As noted
above, representative neutralizing sera (sera # 121 and 122) failed
to generate an enhancing effect upon any of the pseudotype virus
used. The results from this set of experiments suggested that both
neutralizing and enhancing epitopes exist on the E2 envelope
glycoprotein of HCV, and generation of neutralizing antibodies to
E2 may be important for virus neutralization.
Enhancement of infection is mediated by hepatocyte
surface FcR
IHH and Huh7 cells were treated with specific antibodies to the
Fc receptors (CD16, CD32, and CD64). The expression of FcRII
(CD32) was prominent in both cell lines by FACS analysis (56–
64%), while expression of the other Fc receptors (CD16 and
CD64) was significantly less (,10%) (Fig. 5, panels A–B). FcR-
dependent ADE has been demonstrated previously for several
viruses. Further, the use of anti-Fc MAbs has been observed to
inhibit the enhancing properties of the antibodies tested [37].
Here, the use of an Fc-specific Fab fragment inhibited antibody-
mediated enhancement of virus infection by vaccinee sera (Fig. 6,
panel A). Further, enhancement of pseudotype infection in Huh7
cells was also inhibited by treatment of the pseudotype/vaccinee
serum mixture with 5 mg of anti-Fc (Fab) per ml (Fig. 6, panel B).
To further define FcR specificity for ADE, cell culture grown
HCV was separately incubated with vaccinee sera for 1 h at 32uC.
Fifteen minutes prior to infection, cell monolayers were treated
with anti-FcR antibodies, and left as competitors after the addition
of the virus-antibody mixture. Cells were incubated in the
presence of virus for 1 h at 32uC prior to the removal of virus
antibody mixture and addition of fresh medium. In cells pretreated
with a monoclonal antibody directed specifically to FcRII, percent
enhancement attributable to the addition of vaccinee sera was
reduced to levels which were similar to those seen in the absence of
vaccinee sera (Fig. 7, panels A–B).
Discussion
We have evaluated the modulation of HCVcc infectivity by
serum antibodies taken from vaccinated volunteers. A similar
evaluation was made with a VSV/HCV pseudotype system to
clarify results derived from cell culture grown HCV and to analyze
specific points not observable using HCVcc. This led us to
understand the potential for antibody-dependent enhancement of
infection, as observed in closely related virus group, i.e. the
flaviviruses. Our results suggest that inhibition of virus infection
occurs when the ratio of neutralizing antibody to virus is high,
whereas enhancement occurs when this ratio is reversed, as
observed with dengue hemorrhagic fever [36]. We previously
reported the enhancement of VSV/HCV pseudotype infectious
titer in the presence of a number of chronically HCV infected
patient sera, and with human monoclonal antibodies specific for
HCV E2 envelope glycoprotein [20]. A similar evaluation made
with human monoclonal antibodies using HCVcc further
validated our results. These observations suggested that an
enhancement of HCV infection occurs by utilizing a mechanism
which is Fc receptor dependent. The nature of HCV specific
antibodies generated in human subjects was examined in a
susceptible Huh-7 cell line. This phenomenon suggests a potential
problem for some viral infections or vaccines that induce low levels
of neutralizing antibodies. Antibody-mediated enhancement of
infection is sensitive to target cell origin and is dependent on the
types and expression levels of Fc receptors on target cell surface
[22].
Several viruses elicit antibodies that enhance infectivity through
binding of the virus-antibody complex to Fc receptors on cells via
the Fc portion of immunoglobulins [24,38]. This mechanism likely
enhances the interaction between the viral envelope protein and its
receptor to levels outside those observed during normal infection.
Antibody concentrations which fall below levels associated with
neutralization have been observed to induce ADE. Sera from
individuals infected with HIV-1 displayed an ability to neutralize
in vitro infections of HIV-1, but at sub-neutralizing concentrations
Figure 4. Serum induced enhancement is specific for VSV derived pseudotype bearing HCV E2 glycoprotein. VSV/HCV pseudotype
bearing E1 and/or E2 envelope glycoproteins were exposed to serial dilutions of vaccinee sera for 1 h at 37uC prior to infection of Huh-7.5 cells.
Antibody dependent enhancement (panels A–F) and neutralization (panels G–H) of different pseudotype viruses are shown.
doi:10.1371/journal.pone.0023699.g004
Antibody Dependent Enhancement of HCV Infection
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three primary Fc receptors was analyzed by FACS. Results are shown for IHH (panel A) and Huh-7 (panel B).
doi:10.1371/journal.pone.0023699.g005
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Furthermore, the cross protective antibody response of DENV-1
sera for DENV-2 infection was lost at higher dilutions, and
displayed ADE [40]. Enhancement of DENV-2 infection has also
been noted in a rhesus monkey model using passive transfer of
dengue immune sera [31], and an association between increased
viral burden and disease severity has been noted [41]. Recently,
the use of the rhesus monkey as a model has exhibited similar
enhancement using subneutralizing concentrations of a cross
reactive monoclonal antibody [42]. ADE in this model could be
reduced by altering the Fc region of the antibody to limit binding
to Fc receptors, and completely abrogated by a deletion in the
CH2 region; reinforcing an in vivo correlate for ADE. Similarly,
passive transfer of DENV-1 specific antibodies into a mouse model
subsequently infected with a non-lethal dose of DENV-2 increased
the systemic viral burden to multiple tissues and greatly enhanced
the mortality rate of infected mice. Antibodies modified to not
bind FcR were not able to enhance infection in this model,
confirming the importance of specific antibody [43]. Finally, cross
reactive prM-specific antibodies for Dengue serotypes have been
observed to promote ADE in humans, with enhancement being
associated with an increase in the infectivity of poorly infectious
virions lacking prM maturation [44]. Immature virus containing
unprocessed or poorly processed prM - the precursor viral
glycoprotein to the M envelope glycoprotein found in mature,
infectious Dengue virions – thereby becomes a secondary source of
viral infection.
Interestingly, enhancement of HCV infection by vaccinee sera
to genotype 1a glycoproteins appeared to be more prominent for
genotype 2a (clone JFH1). Such results may indicate that
enhancing epitopes occur across genotypes, while neutralizing
epitopes found primarily on the E2 glycoprotein may be more
prone to be subjected to selective pressure. The use of a VSV/
HCV pseudotype expressing a single glycoprotein from the virus
has been used extensively by us [3,20]. These pseudotyped viruses
display extensive differences in ligand sensitivity, and both have
incorporated fusion domains in their native sequences. Our results
suggest that domains within the E2 glycoprotein are the most likely
associated with the enhancement seen in the systems used [20].
Depletion of certain specific competing and/or interfering
antibodies may allow systematic evaluation of the roles played
Figure 6. Enhancement of VSV/HCV pseudotype infection via serum addition is dependent upon Fc region of the IgG. A Fab fragment
was used to block the attachment of the Fc region of virus adsorbed antibody to hepatocytes subsequent to the binding of the antibody to the
pseudotype virus. Non-neutralizing vaccine sera added to pseudotype virus (panel A) or HCVcc (panel B) were treated with 2 mg anti-Fc Fab for 15
minutes prior to addition on Huh-7 cells for infectivity. Virus supernatants treated only with the Fc-Fab fragment were used as controls.
doi:10.1371/journal.pone.0023699.g006
Figure 7. Blocking FcRII on hepatocyte surface leads to
inhibition of ADE. HCV was incubated with vaccinee sera for 1 h
prior to infection. Huh-7 cells were treated with antibodies known to
block the binding activity of the individual Fc receptors 15 minutes
prior to infection with the HCV/vaccinee sera mixture. Cells were
incubated for 6 h, washed, and incubated for 4 days before RNA
preparation and real-time PCR analysis for quantitation of HCV RNA by
real-time PCR.
doi:10.1371/journal.pone.0023699.g007
Antibody Dependent Enhancement of HCV Infection
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HCV infection.
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